The Anti-Longevity PlaybookGet the Playbook
Evidence Review
Semaglutide (Ozempic / Wegovy)
Verdict
ProvenEvidence Tier
A
Strong evidence
Human Studies
Yes — large RCTs
Typical Cost
$300-1,000/mo
Semaglutide has some of the strongest recent clinical trial data of any drug. The SELECT trial (17,604 patients) showed a 20% reduction in major cardiovascular events in overweight/obese individuals. Emerging signals suggest potential cancer risk reduction. This is a genuine paradigm shift in cardiometabolic medicine backed by randomized data, not observational associations.
The full evidence review — including the SELECT trial data that changed cardiometabolic medicine — and the emerging cancer signal — is in Section 9 (GLP-1/GIP Agonists) of The Anti-Longevity Playbook.
Reviewed by Dr. Ramy Khalil, MD · Double Board-Certified Internal Medicine · Last updated March 2026
Does semaglutide improve longevity?
The SELECT trial (17,604 patients) showed 20% reduction in major cardiovascular events. Emerging cancer risk reduction signals add to an already strong evidence base.
Free Chapter
Want the full picture?
Start with a free chapter.
Read the first chapter of The Anti-Longevity Playbook free — including the intervention with stronger mortality data than Semaglutide.
More from GLP-1/GIP Agonists
Browse All Evidence Reviews
30+ longevity interventions reviewed by a physician against the primary literature.
ExerciseStatinsApoB TestingNMNNMN vs. NR — Which Is Better?ResveratrolRapamycinMetformin for LongevityBPC-157PeptidesCold Plunge / Cold ExposureSaunaSleepTestosterone Replacement TherapyGrowth HormoneContinuous Glucose MonitorFull-Body MRI ScreeningBiological Age TestsSemaglutideTirzepatideIntermittent FastingCaloric RestrictionBerberineOmega-3 Fatty AcidsVitamin DMagnesiumCoQ10SpermidineCreatineSocial ConnectionAlcohol